Table 1 Overview of the pediatric tumor patients with detailed information on age, sex, radiotherapy, histology, localization, metastasis and dosage
From: Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients
Drug | Patient # | Age | Sex | RTX | Tumor histology | Localization | Lepto-meningeal metastasis | Dose mg/kg |
|---|---|---|---|---|---|---|---|---|
Imatinib | 1 | 18,3 | m | focal | Germ cell tumor | pineal | yes | 8.51 BID |
2 | 14.5 | f | focal | Glioblastoma | hemispheric | yes | 1.82 QD | |
3 | 7.5 | m | CSI | Plexuscarcinoma | hemispheric | yes | 16.67 QD | |
Dasatinib | 1 | 19.1 | m | focal | Germ cell tumor | pineal | yes | 1.72 BID |
Nintedanib | 4 | 19.4 | m | focal | Ependymoma | hemispheric | yes | 3.72 BID |
5 | 13.5 | m | focal | Ependymoma | hemispheric | no | 3.23 BID | |
6 | 7.6 | m | focal | Ependymoma | posterior fossa | yes | 10.35 QD | |
Panobinostat | 4 | 20.3 | m | focal | Ependymoma | hemispheric | yes | 0.35 3 doses / week |
Regorafenib | 4 | 20.1 | m | focal | Ependymoma | hemispheric | yes | 0.78 QD |
Ribociclib | 7 | 8.4 | f | focal | Epithelioid sarcoma (metastasis) | non CNS primary | yes | 3.33 QD |
Vorinostat | 8 | 10.8 | m | CSI | Medulloblastoma | posterior fossa | yes | 3.74 QD |
9 | 12.7 | f | CSI | Atypical teratoid rhabdoid tumor | hemispheric | yes | 2.63 QD |